Login · Contact

Akorn Pharmaceuticals

Akorn Investor Relations
2017 Press Releases
Webcast ImageWebcast
Q4 2016 Akorn, Inc. Earnings Conference Call (Replay)
03/01/17 at 9:00 a.m. CT
Q4 2016 Akorn, Inc. Earnings Conference Call
Wednesday, March 1, 2017 9:00 a.m. CT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016
DateTitle 
04/24/17Fresenius Kabi to Acquire Akorn
- - - - - Strategically complementary combination to enhance and diversify Fresenius Kabi’s business and portfolio - - - - - At $34.00 a share, transaction valued at approximately $4.3 billion, plus the assumption of debt - - - - - Transaction expected to close by early 2018LAKE ZURICH, Ill. and LAKE FOREST, Ill., April 24, 2017 – Fresenius Kabi has agreed to acquire Akorn (NASDAQ: AKRX), a U.S-based manufacturer and marketer of prescription and over-the-counter pharmaceutical... 
Printer Friendly Version
04/07/17Akorn Confirms Discussions with Fresenius Kabi
LAKE FOREST, Ill., April 07, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today confirmed that Akorn is currently in discussions with Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA (FWB:FRE), concerning a potential acquisition of Akorn. Entry into a formal agreement with respect to a transaction remains subject to, among other things, approval by the Executive Board and Supervisory Board of Fresenius Management SE and t... 
Printer Friendly Version
03/02/17Akorn Receives FDA Approval for Ephedrine Sulfate Injection, USP
LAKE FOREST, Ill., March 02, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generics pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its New Drug Application (NDA) for Ephedrine Sulfate Injection, USP 50 mg/mL in 1 mL single dose ampule.  Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. About Akorn Akorn, I... 
Printer Friendly Version
03/01/17Akorn Provides Fourth Quarter and Full Year 2016 Results and Outlines Full Year 2017 Guidance
- Q4 2016 Revenue Increase to $284 Million - - Q4 2016 GAAP Diluted EPS Decrease of 4% to $0.26; Q4 2016 Adjusted Diluted EPS Decrease of 3% to $0.58 - - FY 2016 Revenue Increase of 13% to $1,117 Million - - FY 2016 GAAP Diluted EPS Increase of 20% to $1.47; FY 2016 Adjusted Diluted EPS Increase of 11% to $2.25 - - Conference Call and Webcast to Be Held March 1, 2017 at 10:00 a.m. EST - LAKE FOREST, Ill., March 01, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty ge... 
Printer Friendly Version
02/28/17Akorn Receives Approval for Mycophenolate Mofetil for Injection, USP
LAKE FOREST, Ill., Feb. 28, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty pharmaceutical company, today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Mycophenolate Mofetil for Injection, USP, 500 mg/vial.  This approval is the first new product approval received out of Akorn’s Decatur, Illinois manufacturing facility since the FDA re-inspection in December 2016. According... 
Printer Friendly Version
02/06/17Akorn to Report Fourth Quarter and Full Year 2016 Results
LAKE FOREST, Ill., Feb. 06, 2017 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq:AKRX), a leading specialty generic pharmaceutical company, today announced that it plans to issue a press release on Wednesday, March 1, 2017 outlining the fourth quarter and full year 2016 results. In addition, the Company will host a conference call at 10:00 am ET on the same day to discuss its fourth quarter and full year 2016 financial results. The dial-in number to access the call is (844) 249-9382 in the U.S. and... 
Printer Friendly Version